

Initiating SGLT2 Inhibitors for Adults in Type 2 Diabetes, Chronic Kidney Disease and Heart Failure

September 2025: Generic Dapagliflozin is the 1st line SGLT2 for ALL patients

The aim of this guidance is to ensure that SGLT2 inhibitors are added appropriately to established therapy.

Chronic Kidney Disease (CKD):

See BSW guidance found here.

Dapagliflozin for treating chronic kidney disease: <u>NICE TA1075</u>. Empagliflozin for treating chronic kidney disease: <u>NICE TA942</u>

Heart failure:

Initiation of an SGLT2 inhibitor should be undertaken by or be discussed with Specialist Teams. Please see Guidelines for the use of Dapagliflozin & Empagliflozin (SGLT2) in Heart Failure

Type 2 diabetes:

Following the update to NICE Guidance NG28 Type 2 diabetes in adults: management in February 2022, the SGLT2 inhibitors (with proven cardiovascular benefit) should now be offered at diagnosis of diabetes for those who have heart failure or established atherosclerotic cardiovascular disease (CVD). In addition, they should be considered at diagnosis for those who are at high risk of developing CVD (QRisk2 or 3 ≥10%).

At any point in the management of diabetes, where there is a change to cardiovascular risk or status change, SGLT2 inhibitors ought to be considered.

Step 1a

- At diagnosis, offer standard release metformin as 1st line therapy titrated to maximum tolerated dose.
- Consider MR if intolerable GI side effects.

Irrespective of HbA1c:
 Offer an SGLT2 inhibit

Step1b

- Offer an SGLT2 inhibitor (not ertugliflozin*) for those with established atherosclerotic CVD or if meets criteria for use in CKD.
- Consider an SGLT2 inhibitor (not ertugliflozin*) in addition to metformin for those at high risk of CVD.

At any stage of treatment

- Offer an SGLT2 inhibitor (not ertugliflozin*) at routine review if develops atherosclerotic CVD or meets criteria for use in CKD.
- Consider adding an SGLT2 inhibitor (not ertugliflozin*) at routine review if becomes at high risk of developing CVD.

The glucose lowering efficacy of SGLT2 inhibitors is reduced when eGFR is < 45 mL/min/1.73m² and is likely absent in patients with severe renal impairment. Therefore, additional glucose lowering treatment should be considered in patients with type 2 diabetes mellitus when eGFR<45.

Adjusting ORAL medication when adding SGLT2 inhibitor with proven CV benefit for cardiorenal protection

SGLT2 inhibitors with proven cardiovascular benefit indicated for T2 Diabetes:

- 1. Generic Dapagliflozin 10mg OD (1st line for all patients) If the patient has intolerance to Dapagliflozin, other options include:
 - a. Empagliflozin 10mg OD, increased to 25mg OD if necessary and tolerated.
 - b. Canagliflozin 100mg OD, increased if tolerated to 300mg OD if required.

*Note that cardiovascular benefits with Ertugliflozin have not been established.

Please see BNF and SmPC for further dose titration and renal impairment adjustment.

For simplicity, Dapagliflozin 10mg is advocated by our local specialists as it is now available generically and has no dose titration or dose adjustment in renal impairment, and it also has a broad product license.

Current regime includes:	Suggested adjustment following discussion with patient:	Monitoring needed:	
		HbA1c target met:	HbA1c target not met:
Metformin only	Up titrate to maximum tolerated dose of Metformin and then add SGLT2 inhibitor.	Repeat HbA1c as per normal	Repeat HbA1c after 3 months and

		schedule (6- 12months).	escalate treatment if target still not met.
Gliclazide (or other Sulfonylurea)	Add SGLT2 inhibitor and reduce dose of Sulfonylurea by 50% where HbA1c target achieved or if within 10mmol of target. Where HbA1c exceeds target by >10mmol,	Repeat HbA1c at 3 months.	Repeat HbA1c after 3 months and escalate treatment if target still not met.
	add SGLT2 inhibitor.	Check fasting blood g week after changes. (reduced or stopped a	Gliclazide can be
Alogliptin/Linagliptin Saxagliptin/Sitagliptin	Swap for SGLT2 inhibitor. if eGFR>45.	Repeat HbA1c as per normal	Repeat HbA1c after 3 months and
	Add SGLT2 inhibitor. if eGFR <45	schedule (6- 12months).	escalate treatment if target still not met.
Pioglitazone	Add SGLT2 inhibitor.	Repeat HbA1c as per normal schedule (6-12months).	Repeat HbA1c after 3 months and escalate treatment if target still not met.

Benefits of SGLT2 inhibitors

- Up to 10mmol/mol reduction in HbA1c (dependent on starting level)
- Low incidence of hypoglycaemia (effect proportional to blood glucose)
- Weight loss (up to 3kg)
- Cardioprotective benefit, reduces progression of chronic complications affecting cardiovascular system and kidneys. (N.B. not applicable to ertugliflozin)

SGLT2 inhibitors can drop blood pressure (~5mm/Hg) and so a review of antihypertensives may be necessary.

SGLT2 Inhibitors should NOT be used where:

- History of diabetic ketoacidosis (DKA)
- Ketogenic or very low carbohydrate diet
- Currently unwell (acute illness, surgery or planned procedure)
- Pregnancy or risk of pregnancy
- Breast feeding
- Type 1 diabetes

SGLT2 Inhibitors should be used with CAUTION where:

- History of persistent or complicated UTI
- Frail and elderly
- Severe hepatic impairment
- Consult SmPC to see if dose adjustment is required in patients with renal impairment

Provide information to the patient on:

Potential side effects and when to seek review notably to report severe pain/tenderness/erythema/swelling in the
genital/perineal area and importance of preventative foot care.

Please see MHRA Drug Safety Updates: SGLT2 inhibitors: reports of Fournier's gangrene and SGLT2 inhibitors: updated advice on increased risk of lower limb amputation

- Sick day guidance- see below (stop Dapagliflozin if diarrhoea/vomiting or symptoms of DKA and do not restart until eating/drinking normally for at least 24 hours).
- Staying hydrated.

Risk of DKA and SGLT2 inhibitors

The risk of DKA must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness.

Patients should be assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level.

Test strips for monitoring ketone levels should not routinely be prescribed in T2D patients who take SGLT2 inhibitors. A strong emphasis should be placed on patient education of symptoms of DKA and seeking urgent medical assessment in the event of symptoms rather than encouraging home monitoring.

Please see MHRA Drug Safety Updates: SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis and SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness

Written Information for Patients

Trend leaflet Type 2 diabetes: What to do when you are ill - Trend Diabetes

Arden's have information leaflets [Medicines and Dehydration "Medicine Sick Day Guidance" and Sodium-glucose Co-transporter (SGLT2) Inhibitors – see appendix for images] that can be personalised and a read code can be input to document that advice has been provided [Y3767 information given re sick day rules or Y308a Medication side-effect education:SGLT2i].

Seek advice from Specialist Teams if guidance required.


Specialist Team	Telephone	Email
BaNES DSN	07876 265064	ruh-tr.communitydsn@nhs.net
Swindon DSN	01793 463841	SWICCG.CommunityDiabetesService@nhs.net
Wiltshire DSN	North, East and West 01248 456	whc.diabetesnurses@nhs.net
	483	
	South 012722 425 176	7

References

- 1. National Institute for Health and Care Excellence. NG203. Chronic kidney disease: assessment and management, updated November 2021. Available from https://www.nice.org.uk/guidance/ng203
- 2. National Institute for Health and Care Excellence. NG 28. Type 2 diabetes in adults: management, updated June 22. Available from https://www.nice.org.uk/guidance/ng28
- 3. National Institute for Health and Care Excellence. British National Formulary. Accessed May 2022. Available from https://bnf.nice.org.uk
- 4. Summary of Product Characteristics. Accessed May 2022. Available from https://www.medicines.org.uk

Appendix

Arden's Information leaflets



NHS

NHS Number: <NHS number>

<Patient name> <Patient Address>

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors

Dear <Patient Name>

You are currently taking a SGLT2 inhibitor called < Medication>.

Take this medication according to the instructions from your prescriber. Please make sure you understand how to take the medicine and ask if you have any questions.

- now to take the medicine and ask if you have any questions.

 This is an effective treatment for diabetes and/or heart failure, but it can have some side effects, including:

 Hypoglycaemia (pow blood glucose) This usually only occurs if taken in combination with other disbetes medicines and your prescriber may therefore need to alter the dose.

 Dehydration This medicine increases your urine volume so may cause dehydration. To grevent dehydration, you must drink at least two litres of non-sugary drinks aday, unless directed otherwise.

 Genital infections Ast his medicine increases the glucose (sugar) in your urine, there is an increased risk of infection, such as gental thrush. Wash your cental area with warm water using non-perfuned soap and avoid wearing tight underwear to reduce the risk of infection.

In rare cases, SGLT2 Inhibitors can cause more serious side effects, including diabetic ketoacidosis (DKA), Fournier's sargrena and lower-limb amputation. Please seek medical advice immediately if you have any of the following:

- Rapid weight loss

- Feeling or being sick, or stomach pain

- Fast and force.

- lowing:
 Rapid weight loss
 Feeling or being sick, or stomach pain
 Feat and deep breathing
 Sweet or metallic taste in the mouth
 Different cloaur by our breath, univer or sweat
 Severe pain, tendemess, redness, or swelling 'down below', accompanied by fever or feeling unwell

It is important you attend for regular foot checks whilst taking this medication.

If you become unwell and have vomiting, diarrhoea, or fever, you should stop this medication. You can restart when you are better (eating and drinking normally), however if you remain unwell after 48 hours seek medical advice from your GP, Pharmacist or NHS 11.

The following blood tests are required to monitor your treatment, at least once a year. If you haven't had one in the last year, please book a blood test with your GP practice.

Blood Test	My last results	Resson for test
HbA1c	<numerics></numerics>	To monitor diabetes (if prescribed for diabetes)
eGFR	<numerics></numerics>	To check how your kidneys are working
Creatinine	<numerics></numerics>	To check how your kidneys are working

Notes:

Your next appointment is: